SciSparc Ltd. - Ordinary Shares (SPRC) is currently showing a neutral headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently no clear earnings read.
HEADLINE TAKE: The current headline mix looks balanced, so the overall news tone reads neutral right now.
Change stock
Search another ticker to view its latest news page.
Full chart, indicators and drawing tools on TradingView. Move to Platforms when you are ready to act.
MyStockHarbor.com
NEWS SCORE
50/100
Neutral
Bearish
Neutral
Bullish
Earnings Tone
55
Neutral based on actual EPS/revenue
Confidence
Low
Headline depth
Last Price
$4.90
Trend Context
Mixed / range
Latest briefing
What's happening with SPRC
globenewswire.com15 Jul 2026
SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome
TEL AVIV, Israel, July 15, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its subsidiary NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, announced the initiation of its Phase IIb clinical trial site at Hannover Medical School, Hanover, Germany (“MHH”), for SCI-110, its proprietary cannabinoid-based treatment candidate for Tourette Syndrome (TS)…
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
thenewswire.com2 Jul 2026
NeuroThera Labs Announces Upsize to Private Placement
Toronto, ON – July 2, 2026 - TheNewswire – NeuroThera Labs Inc. (the “ Company ” or “ NeuroThera ”) (TSXV: NTLX) a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), is pleased to announce that, further to its press release dated June 30, 2026, it has increased the size of its previously announced non-brokered private placement (the " Offering ") and extended the expiry term of the Unit Warrants (as defined below). The Company now intends to issue up to 45,000,000 units…
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
thenewswire.com30 Jun 2026
NeuroThera Labs Announces C$5,000,000 Private Placement of Units
Toronto, ON – TheNewswire - June 30, 2026 – NeuroThera Labs Inc. (the “ Company ” or “ NeuroThera ”) (TSXV: NTLX) a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), is pleased to announce that it will be proceeding with a non-brokered private placement of up to 37,050,000 units (the " Offered Units ") at a price of C$0.135 per Offered Unit for gross proceeds of up to approximately C$5,000,000 (the " Offering "). Each Offered Unit will be comprised of one (1) common sha…
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
Older updates drop into a lighter feed
globenewswire.com
4 Jun 2026
SciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum
